ID   NT-3
AC   CVCL_VG81
DR   cancercelllines; CVCL_VG81
DR   Wikidata; Q54931073
RX   CelloPub=CLPUB00598;
RX   PubMed=29330294;
RX   PubMed=36269546;
CC   Doubling time: 10.9 +- 0.7 days (PubMed=29330294).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr541Ala (c.1621A>G); ClinVar=VCV000134640; Zygosity=Homozygous; Note=Probable SNP (PubMed=29330294).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C45835; Pancreatic neuroendocrine tumor G2
DI   ORDO; Orphanet_97253; Neuroendocrine tumor of pancreas
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 10-09-24; Version: 11
//
RX   CelloPub=CLPUB00598;
RA   Behrang Y.;
RT   "Establishment and characterization of a new human, highly
RT   differentiated and functionally active tumor model of a pancreatic
RT   neuroendocrine tumor.";
RL   Thesis MD (2020); University of Hamburg; Hamburg; Germany.
//
RX   PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163;
RA   Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G.,
RA   Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M.,
RA   Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M.,
RA   Izbicki J.R., Lohse A.W., Schrader J.;
RT   "Establishment of the first well-differentiated human pancreatic
RT   neuroendocrine tumor model.";
RL   Mol. Cancer Res. 16:496-507(2018).
//
RX   PubMed=36269546; DOI=10.1007/s13402-022-00727-z; PMCID=PMC9747820;
RA   Viol F., Sipos B., Fahl M., Clauditz T.S., Amin T., Kriegs M.,
RA   Nieser M., Izbicki J.R., Huber S., Lohse A.W., Schrader J.;
RT   "Novel preclinical gastroenteropancreatic neuroendocrine neoplasia
RT   models demonstrate the feasibility of mutation-based targeted
RT   therapy.";
RL   Cell. Oncol. (Dordr.) 45:1401-1419(2022).
//